. . . . . . . . . "gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase 1 1 patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in blast crisis bc accelerated phase ap or in chronic phase cp after failure of interferon alpha therapy 1 2 adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 3 pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia ph all in combination with chemotherapy 1 4 adult patients with myelodysplastic myeloproliferative diseases mds mpd associated with pdgfr platelet derived growth factor receptor gene re arrangements as determined with an fda approved test 1 5 adult patients with aggressive systemic mastocytosis asm without the d816v c kit mutation as determined with an fda approved test or with c kit mutational status unknown 1 6 adult patients with hypereosinophilic syndrome hes and or chronic eosinophilic leukemia cel who have the fip1l1 pdgfri fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes and or cel who are fip1l1 pdgfri fusion kinase negative or unknown 1 7 adult patients with unresectable recurrent and or metastatic dermatofibrosarcoma protuberans dfsp 1 8 patients with kit cd117 positive unresectable and or metastatic malignant gastrointestinal stromal tumors gist 1 9 adjuvant treatment of adult patients following resection of kit cd117 positive gist 1 1 newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase patients with philadelphia chromosome positive chronic myeloid leukemia in blast crisis accelerated phase or in chronic phase after failure of interferon alpha therapy adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia ph all in combination with chemotherapy adult patients with myelodysplastic myeloproliferative diseases associated with pdgfr platelet derived growth factor receptor gene re arrangements as determined with an fda approved test see dosage and administration 2 6 adult patients with aggressive systemic mastocytosis without the d816v c kit mutation as determined with an fda approved test see dosage and administration 2 7 adult patients with hypereosinophilic syndrome and or chronic eosinophilic leukemia who have the fip1l1 pdgfri fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes and or cel who are fip1l1 pdgfri fusion kinase negative or unknown adult patients with unresectable recurrent and or metastatic dermatofibrosarcoma protuberans patients with kit cd117 positive unresectable and or metastatic malignant gastrointestinal stromal tumors adjuvant treatment of adult patients following complete gross resection of kit cd117 positive gist" . . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "ZRbmjttYz8/8fNcz+7/9vPZbPlUEBMHVj2RfroMZeneTxeq0qDiyznP+cpfatpOaEfoJErLAbm3/76sGTQRmtN1TJPWvmRWQWoDZYEvOaghUUttkN6wO3FB4WN31PkNQo3rVt2h1JMGOOs328V13DMXZsVokEzJZgQWM8dvCWX4=" . . "2021-07-03T14:18:50.693+02:00"^^ . . . . .